Pediatric study bill
This article was originally published in The Tan Sheet
Executive Summary
FDA's authority to require drug sponsors to conduct trials in children would expire at the same time as the pediatric exclusivity incentive program under a bill passed by the Senate July 23. Amendment to S 650 makes the bill applicable to all NDAs submitted "on or after April 1, 1999," the same date FDA's pediatric rule first took effect. Amendment also explains how deferral or waivers granted by FDA would apply retroactively. American Academy of Pediatrics supported amendment, but opposed the bill along with Democratic Sens. Christopher Dodd (Conn.), Hillary Clinton (N.Y.), Edward Kennedy (Mass.)...
You may also be interested in...
Pediatric Research Equity Act
S 650 "will provide FDA with additional authority to require pediatric studies of pharmaceutical products when such studies are needed to ensure the safe and effective use of the products in children," agency notes in Nov. 19 release. Bill was presented to President Bush Nov. 21. An amendment linking the expiration of the S 650 to the pediatric exclusivity incentive program remains in the bill (1"The Tan Sheet" Aug. 4, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.